Involvement of various chemokine/chemokine receptor axes in trafficking and oriented locomotion of mesenchymal stem cells in multiple sclerosis patients

Cytokine ◽  
2021 ◽  
Vol 148 ◽  
pp. 155706
Author(s):  
Gholamhossein Hassanshahi ◽  
Mohammad Amin Roohi ◽  
Seyed-Alireza Esmaeili ◽  
Hossein Pourghadamyari ◽  
Reza Nosratabadi
Keyword(s):  
Multiple Sclerosis ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Chemokine Receptor ◽  
Multiple Sclerosis Patients

scholarly journals Feasibility of mesenchymal stem cell culture expansion for a phase I clinical trial in multiple sclerosis

2018 ◽  
Vol 4 (1) ◽  
pp. 205521731876528 ◽  
Author(s):  
Sarah M Planchon ◽  
Karen T Lingas ◽  
Jane Reese Koç ◽  
Brittney M Hooper ◽  
Basabi Maitra ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Stem Cells ◽  
Cell Culture ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Phase I ◽  
Mesenchymal Stem Cell Culture ◽  
Stem Cell Culture ◽  
Multiple Sclerosis Patients

Background Multiple sclerosis is an inflammatory, neurodegenerative disease of the central nervous system for which therapeutic mesenchymal stem cell transplantation is under study. Published experience of culture-expanding multiple sclerosis patients’ mesenchymal stem cells for clinical trials is limited. Objective To determine the feasibility of culture-expanding multiple sclerosis patients’ mesenchymal stem cells for clinical use. Methods In a phase I trial, autologous, bone marrow-derived mesenchymal stem cells were isolated from 25 trial participants with multiple sclerosis and eight matched controls, and culture-expanded to a target single dose of 1–2 × 106 cells/kg. Viability, cell product identity and sterility were assessed prior to infusion. Cytogenetic stability was assessed by single nucleotide polymorphism analysis of mesenchymal stem cells from 18 multiple sclerosis patients and five controls. Results One patient failed screening. Mesenchymal stem cell culture expansion was successful for 24 of 25 multiple sclerosis patients and six of eight controls. The target dose was achieved in 16–62 days, requiring two to three cell passages. Growth rate and culture success did not correlate with demographic or multiple sclerosis disease characteristics. Cytogenetic studies identified changes on one chromosome of one control (4.3%) after extended time in culture. Conclusion Culture expansion of mesenchymal stem cells from multiple sclerosis patients as donors is feasible. However, culture time should be minimized for cell products designated for therapeutic administration.

Natural conditioning of mesenchymal stem cells from multiple sclerosis patients enhances their immune-modulating potential

Cytotherapy ◽  
2019 ◽  
Vol 21 (5) ◽  
pp. e12
Author(s):  
F. Jamali ◽  
M. Hassouneh ◽  
D. Alhattab ◽  
H. Khwaireh ◽  
A. Awidi
Keyword(s):  
Multiple Sclerosis ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Multiple Sclerosis Patients

Evaluation of Cytokines in Multiple Sclerosis Patients Treated with Mesenchymal Stem Cells

2013 ◽  
Vol 44 (4) ◽  
pp. 266-272 ◽  
Author(s):  
Mandana Mohyeddin Bonab ◽  
Maryam Mohajeri ◽  
Mohammad Ali Sahraian ◽  
Mahboubeh Yazdanifar ◽  
Aida Aghsaie ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Multiple Sclerosis Patients

scholarly journals Immunomodulatory Potential of Human Mesenchymal Stem Cells and their Exosomes on Multiple Sclerosis

2021 ◽  
Author(s):  
Hussein Baharlooi ◽  
Zahra Salehi ◽  
Moein Minbashi Moeini ◽  
Nima Rezaei ◽  
Maryam Azimi
Keyword(s):  
Multiple Sclerosis ◽  
Stem Cells ◽  
T Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Interleukin 17 ◽  
Healthy Individuals ◽  
Healthy Control ◽  
Multiple Sclerosis Patients

Purpose: Promising advances have been made in mesenchymal stem cell transplantation to re-induce the immune tolerance in neuroinflammatory animal models and Multiple Sclerosis patients. The available evidence demonstrated that immunomodulatory effects of mesenchymal stem cell are particularly exerted through releasing exosomes to their environment. We therefore, aimed to comparatively assess the potential effect of mesenchymal stem cells and mesenchymal stem cells-derived exosomes on proliferation and function of the CD4+CD25− conventional T cells, isolated from relapsing-remitting Multiple Sclerosis patients. Methods: Mesenchymal stem cells were isolated from human umbilical cord tissues and used for exosome isolation via ultracentrifugation. Both mesenchymal stem cells and mesenchymal stem cells-derived exosomes were evaluated for their anti-inflammatory effects against the proliferation of T cells isolated from two groups of individuals in vitro, MS patients and healthy subjects. Cytokine production of conventional T cells (interferon-γ, interleukin-10, and interleukin-17) was also assessed, using flow cytometry for the patients and healthy individuals. Results: Here, evidence shows that MSCs and MSC-derived exosomes dampen proliferation and percentage of conventional T cells that produce IFN-γ (healthy control: p<0.001) and interleukin-17 (healthy control: p<0.001, MS patients: p<0.001), with a significant increase of IL-10 producing cells in the patients and healthy individuals. Surprisingly, MSC-derived exosomes demonstrated higher immune-modulating properties on conventional T cells responses, compared to MSCs. Conclusion: The current study, provides a novel approach of exocytosis on autoimmune therapy. In particular, Mesenchymal stem cell -derived exosomes, which are cell-derived biologics, could be considered as an alternative for Mesenchymal stem cells in treating multiple sclerosis.

Effects of mesenchymal stem cells transplantation on multiple sclerosis patients

Neuropeptides ◽  
2020 ◽  
Vol 84 ◽  
pp. 102095
Author(s):  
Shirin Barati ◽  
Fatemeh Tahmasebi ◽  
Faeze Faghihi
Keyword(s):  
Multiple Sclerosis ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cells Transplantation ◽  
Multiple Sclerosis Patients

Cytokines production in multiple sclerosis patients after intravenous infusion of autologous mesenchymal stem cells

2014 ◽  
Vol 275 (1-2) ◽  
pp. 192-193
Author(s):  
Darya Nizheharodava ◽  
Mariya Yurkevich ◽  
Halina Ivanchyk ◽  
Svetlana Kulinich ◽  
Marina Zafranskaya
Keyword(s):  
Multiple Sclerosis ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Intravenous Infusion ◽  
Autologous Mesenchymal Stem Cells ◽  
Multiple Sclerosis Patients

In vitro assessment of mesenchymal stem cells immunosuppressive potential in multiple sclerosis patients

2013 ◽  
Vol 149 (1-2) ◽  
pp. 9-18 ◽  
Author(s):  
Marina M. Zafranskaya ◽  
Darya B. Nizheharodova ◽  
Mariya Yu. Yurkevich ◽  
Natallia V. Lamouskaya ◽  
Yana M. Motuzova ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
In Vitro Assessment ◽  
Multiple Sclerosis Patients
Sign in / Sign up

Export Citation Format

Share Document